Programmed death ligand-1 expression in non-small cell lung cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Targeting the programmed cell death ligand-1 (PD-L1) and its receptor PD-1 interaction shows promise in cancer therapy.
• Accurate assessment of PD-L1 expression is vital for understanding its role in non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To determine the frequency and prognostic value of PD-L1 expression in NSCLC using validated methods.
• To assess the specificity of antibodies and in situ mRNA hybridization for PD-L1 detection.

Main Methods:

• Utilized quantitative fluorescence (QIF) and in situ mRNA hybridization (RNAscope) to measure PD-L1.
• Validated antibodies and methods using a control tissue microarray (TMA).
• Assessed two independent NSCLC cohorts (340 Greek, 204 Yale) on TMAs.

Main Results:

• One of four PD-L1 antibodies (5H1) showed validated specificity.
• PD-L1 protein expression was found in 36% (Greek) and 25% (Yale) of NSCLC cases.
• Higher PD-L1 expression (protein and mRNA) correlated with significantly better patient outcomes in both cohorts (P=0.036, P=0.027).
• PD-L1 expression was an independent prognostic factor for better outcome.

Conclusions:

• PD-L1 expression, detected by validated methods, is associated with a better prognosis in NSCLC.
• Antibody specificity is a critical consideration for accurate PD-L1 measurement.
• Further research is needed to establish PD-L1's role in prognosis and predicting treatment response.